Administration of Oral linoleic acid immediately before glucose load slows elevation of postprandial blood sugar level

Written By :  Dr. Kamal Kant Kohli
Published On 2023-08-26 05:45 GMT   |   Update On 2023-08-26 11:00 GMT
Advertisement

Japan: A recent study has shown that oral administration of linoleic acid (LA), a GPR40 and GPR120 agonist, immediately before glucose load improved postprandial hyperglycemia.

The researchers suggest that it may be due to the slowing of gastric emptying via the promotion of GLP-1 secretion and the mechanisms may be associated with the GPR120 pathway. 

The findings, published in Frontiers in Pharmacology, imply that linoleic acid contained in dietary fat may, therefore, improve postprandial hyperglycemia in patients with type 1 diabetes mellitus

Advertisement

Fatty acids are a major nutrient in dietary fat, some of which are ligands of long-chain fatty acid receptors, including GPR 40 (G-protein-coupled receptor) and GPR120. Pretreatment with GPR40 agonists enhanced insulin secretion in response to elevated blood glucose levels after glucose load in a diabetes model, but pretreatment with GPR120 agonists did not ameliorate postprandial hyperglycemia.

Yuta Yamamoto, Wakayama Medical University, Wakayama, Japan, and colleagues investigated whether oral administration of LA immediately before glucose load would impact the elevation of postprandial blood glucose levels in rats.

The study included male rats and rats with type 1 diabetes (T1D) administered streptozocin. They were orally administered LA, trilinolein, α-linolenic acid (α-LA), oleic acid, TAK-875, or TUG-891 immediately before glucose load.

Measurement of blood glucose levels was done before, then 15, 30, 60 and 120 min after the glucose load. The uptake of [14C] α-MDG for 30 min with or without LA was measured using CACO-2 cells.

15 and 30 min after glucose load, from rats administered LA was collected. Blood samples were collected for measurement of GLP-1 (glucagon-like peptide 1) and cholecystokinin concentrations.

The study revealed the following findings:

  • The elevation of postprandial blood glucose levels was slowed by linoleic acid but not by trilinolein in rats without promotion of insulin secretion, and this effect was also observed in rats with type 1 diabetes.
  • The uptake of α-MDG, an SGLT-specific substrate, was, however, not inhibited by LA.
  • Gastric emptying was slowed by LA 15 min after glucose load, and GLP-1, but not cholecystokinin, level was elevated by LA 15 min after glucose load.
  • TUG-891, a GPR120 agonist, ameliorated postprandial hyperglycemia but TAK-875, a GPR40 agonist, did not.
  • Pretreatment with AH7614, a GPR120 antagonist, partially cancelled the improvement of postprandial hyperglycemia induced by LA.
  • α-LA, which has a high affinity with GPR120 and LA, slowed the elevation of postprandial blood glucose levels, but oleic acid, which has a lower affinity with GPR120 than LA, did not.

"Oral administration of free LA, a GPR120 agonist, immediately before glucose load improved postprandial glucose levels independent from insulin," the researchers concluded.

Reference:

Yamamoto, Y., Narumi, K., Yamagishi, N., Nishi, T., Ito, T., Iseki, K., Kobayashi, M., & Kanai, Y. (2023). Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1197743

Tags:    
Article Source : Frontiers in Pharmacology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News